The sigma-2 receptor as a therapeutic target for drug delivery in triple negative breast cancer.

[1]  Giorgio Mustacchi,et al.  The role of taxanes in triple-negative breast cancer: literature review , 2015, Drug design, development and therapy.

[2]  R. Mach,et al.  Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV‐134 , 2014, Molecular oncology.

[3]  R. Mach,et al.  Conjugation to a SMAC mimetic potentiates sigma-2 ligand induced tumor cell death in ovarian cancer , 2014, Molecular Cancer.

[4]  R. Mach,et al.  Functional assays to define agonists and antagonists of the sigma-2 receptor. , 2014, Analytical biochemistry.

[5]  R. Mach,et al.  Sigma-2 receptor ligand as a novel method for delivering a SMAC mimetic drug for treating ovarian cancer , 2013, British Journal of Cancer.

[6]  R. Mach,et al.  Quantitative Receptor-Based Imaging of Tumor Proliferation with the Sigma-2 Ligand [18F]ISO-1 , 2013, PloS one.

[7]  T. Fehm,et al.  Possible role of PGRMC1 in breast cancer development , 2013, Climacteric : the journal of the International Menopause Society.

[8]  S. Ran,et al.  TLR4 Is a Novel Determinant of the Response to Paclitaxel in Breast Cancer , 2013, Molecular Cancer Therapeutics.

[9]  R. Hotchkiss,et al.  Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site , 2011, Nature communications.

[10]  Jonathan B. Mitchem,et al.  The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine , 2010, Molecular Cancer.

[11]  R. Mach,et al.  New N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl phenylcarbamate analogs as sigma2 receptor ligands: synthesis, in vitro characterization, and evaluation as PET imaging and chemosensitization agents. , 2009, Bioorganic & medicinal chemistry.

[12]  Shaomeng Wang,et al.  Design of Small‐Molecule Peptidic and Nonpeptidic Smac Mimetics , 2009 .

[13]  S. Narod,et al.  Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.

[14]  Kathryn Trinkaus,et al.  Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy , 2007, Molecular Cancer.

[15]  R. Hotchkiss,et al.  Subcellular localization of sigma-2 receptors in breast cancer cells using two-photon and confocal microscopy. , 2007, Cancer research.

[16]  C. Perou,et al.  The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.

[17]  R. Mach,et al.  Synthesis of N-substituted 9-azabicyclo[3.3.1]nonan-3α-yl carbamate analogs as σ2 receptor ligands , 2006 .

[18]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[19]  R. Mach,et al.  Characterization of a novel iodinated sigma-2 receptor ligand as a cell proliferation marker. , 2006, Nuclear medicine and biology.

[20]  R. Mach,et al.  [3H]N-[4-(3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)butyl]-2-methoxy-5-methylbenzamide: a novel sigma-2 receptor probe. , 2005, European journal of pharmacology.

[21]  Philip M. Long,et al.  Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[22]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[23]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[25]  Xiaodong Wang,et al.  Smac, a Mitochondrial Protein that Promotes Cytochrome c–Dependent Caspase Activation by Eliminating IAP Inhibition , 2000, Cell.

[26]  R. Mach,et al.  Sigma-2 receptors as a biomarker of proliferation in solid tumours , 2000, British Journal of Cancer.

[27]  S. Homan,et al.  Overexpression of σ Receptors in Nonneural Human Tumors , 1991 .

[28]  J. Pietenpol,et al.  Subtyping of triple‐negative breast cancer: Implications for therapy , 2015, Cancer.

[29]  R. Mach,et al.  Synthesis of N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl carbamate analogs as sigma2 receptor ligands. , 2006, Bioorganic & medicinal chemistry.

[30]  R. Mach,et al.  Sigma 2 receptors as potential biomarkers of proliferation in breast cancer. , 1997, Cancer research.

[31]  S. Homan,et al.  Overexpression of sigma receptors in nonneural human tumors. , 1991, Cancer research.